Lacklustre Debut For LIC, India's Biggest IPO, Shares Close 8% Lower: Developments
- The insurance behemoth's shares ended at Rs 875.45, about 7.75 per cent lower than its issue price and almost flat from its listing price. LIC's shares traded between a low of Rs 860.10 and a high of Rs 920.
- India's biggest-ever IPO, state-owned insurance giant LIC, listed its shares at a discount of over 8 per cent on the BSE and the NSE on Tuesday.
- On the BSE, LIC launched at Rs 867.20 per share, a discount of 8.62 per cent from its mega initial public offering (IPO) allotment price of Rs 949. On the NSE, LIC's listing price was ₹ 872, indicating a discount of 8.11 per cent from the issue price.Â
- LIC had fixed the issue price of its shares at ₹ 949 apiece after a successful issue, which fetched ₹ 20,557 crore to the government.
- The tepid listing has resulted in a sharp drop in the market capitalisation (m-cap) of the country's largest insurer.Â
- At the issue price of Rs 949, the m-cap of LIC stood at Rs 6,00,242 crore. At the listing price, the valuation of LIC dipped to Rs 5,57,675 crore, resulting in a loss of around Rs 42,500 crore.
- Still, the country's largest insurer, LIC, is the fifth most valuable company in India, with a m-cap of about Rs 5.54 lakh crore.
- That tepid debut comes on a day when the broader equity benchmarks rallied for the second consecutive day, snapping a six-session losing streak.
- Despite wild gyrations in global financial markets, LIC's IPO got an overwhelming response. The offer was oversubscribed nearly three times, led by policyholders who bid for over six times the shares on offer.
- The government sold over 22.13 crore shares or a 3.5 per cent stake in LIC through the IPO, a third of its original target plan.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets